Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
https://www.zacks.com/stock/news/2261543/boston-scientific-bsx-q1-earnings-beat-estimates-view-raised?cid=CS-ZC-FT-analyst_blog|earnings_article-2261543
Apr 24, 2024 - Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
0
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
https://www.zacks.com/stock/news/2257821/icon-iclr-gains-from-new-offerings-strategic-acquisitions?cid=CS-ZC-FT-analyst_blog|zer_report_update-2257821
Apr 18, 2024 - ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
0
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
https://www.zacks.com/stock/news/2256957/abbott-abt-q1-earnings-beat-estimates-margins-contract?cid=CS-ZC-FT-analyst_blog|earnings_article-2256957
Apr 17, 2024 - Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
0
1 Beaten-Down Cathie Wood Stock to Buy and Hold
https://www.fool.com/investing/2024/04/04/1-beaten-down-cathie-wood-stock-to-buy-and-hold/?source=iedfolrf0000001
Apr 04, 2024 - This company is innovating where it matters most, which could prove highly lucrative down the road.
0
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
https://www.zacks.com/stock/news/2245870/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2245870
Mar 26, 2024 - Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
0
2 Beaten-Down Cathie Wood Stocks With Massive Potential
https://www.fool.com/investing/2024/03/11/2-beaten-down-cathie-wood-stocks-with-massive/?source=iedfolrf0000001
Mar 10, 2024 - They won't lag the market forever.
0
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2229711/exact-sciences-exas-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2229711
Feb 21, 2024 - Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
https://www.zacks.com/stock/news/2229451/axsome-axsm-stock-falls-despite-q4-earnings-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2229451
Feb 21, 2024 - Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
0
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
https://www.zacks.com/stock/news/2227759/iovance-iova-stock-rises-on-fda-nod-for-melanoma-drug-amtagvi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227759
Feb 19, 2024 - The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
0
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
https://www.zacks.com/stock/news/2227354/ironwood-irwd-q4-earnings-miss-revenues-beat-marginally?cid=CS-ZC-FT-analyst_blog|earnings_article-2227354
Feb 16, 2024 - Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
0
Pages: 12
Page 1